IL303629A - Recombinant cd3 binding proteins and their use - Google Patents

Recombinant cd3 binding proteins and their use

Info

Publication number
IL303629A
IL303629A IL303629A IL30362923A IL303629A IL 303629 A IL303629 A IL 303629A IL 303629 A IL303629 A IL 303629A IL 30362923 A IL30362923 A IL 30362923A IL 303629 A IL303629 A IL 303629A
Authority
IL
Israel
Prior art keywords
ankyrin repeat
seq
amino acid
acid sequence
protein
Prior art date
Application number
IL303629A
Other languages
English (en)
Hebrew (he)
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of IL303629A publication Critical patent/IL303629A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL303629A 2020-12-16 2021-12-16 Recombinant cd3 binding proteins and their use IL303629A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063126356P 2020-12-16 2020-12-16
EP20216705 2020-12-22
US202163182394P 2021-04-30 2021-04-30
PCT/EP2021/086331 WO2022129428A1 (en) 2020-12-16 2021-12-16 Recombinant cd3 binding proteins and their use

Publications (1)

Publication Number Publication Date
IL303629A true IL303629A (en) 2023-08-01

Family

ID=79282877

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303629A IL303629A (en) 2020-12-16 2021-12-16 Recombinant cd3 binding proteins and their use

Country Status (9)

Country Link
US (1) US20240052033A1 (enExample)
EP (1) EP4263608A1 (enExample)
JP (1) JP2023554379A (enExample)
KR (1) KR20230120139A (enExample)
AU (1) AU2021403658A1 (enExample)
CA (1) CA3202296A1 (enExample)
IL (1) IL303629A (enExample)
MX (1) MX2023007067A (enExample)
WO (1) WO2022129428A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4149959A1 (en) 2020-05-14 2023-03-22 Molecular Partners AG Multispecific proteins
IL305677A (en) 2021-03-09 2023-11-01 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
EP4447990A1 (en) 2021-12-14 2024-10-23 Molecular Partners AG Designed repeat domains with dual binding specificity and their use
EP4724486A1 (en) 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd2 binding proteins and their use
WO2025163144A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager
WO2026093563A2 (en) 2024-10-31 2026-05-07 Molecular Partners Ag Multispecific binding proteins and their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
CN113278077A (zh) 2010-11-26 2021-08-20 分子组合公司 设计的与血清白蛋白结合的重复蛋白
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
BR112017020986A2 (pt) 2015-04-02 2018-08-14 Molecular Partners Ag. proteínas de ligação recombinantes e seu uso
CN121499810A (zh) * 2018-09-28 2026-02-10 剑桥企业有限公司 疫苗和方法
CN114222757A (zh) * 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
JP7611173B2 (ja) * 2019-06-04 2025-01-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えｆａｐ結合タンパク質及びそれらの使用

Also Published As

Publication number Publication date
KR20230120139A (ko) 2023-08-16
EP4263608A1 (en) 2023-10-25
AU2021403658A1 (en) 2023-06-29
MX2023007067A (es) 2023-08-09
CA3202296A1 (en) 2022-06-23
US20240052033A1 (en) 2024-02-15
WO2022129428A1 (en) 2022-06-23
JP2023554379A (ja) 2023-12-27

Similar Documents

Publication Publication Date Title
US20240052033A1 (en) Recombinant cd3 binding proteins and their use
EP4245317A1 (en) Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody
US20220242973A1 (en) Recombinant fap binding proteins and their use
KR20210030956A (ko) Pd-l1 및 cd137에 결합하는 항체 분자
TW202019963A (zh) 結合cd137及ox40的抗體分子
US20220298212A1 (en) Recombinant 4-1bb binding proteins and their use
US11834504B2 (en) DARPin based multi-specific t-cell engagers
WO2021102624A1 (en) Covalent protein drugs developed via proximity-enabled reactive therapeutics (perx)
WO2021116470A2 (en) Recombinant peptide-mhc complex binding proteins and their generation and use
EP4724460A1 (en) Recombinant cd16a binding proteins and their use
AU2024286934A1 (en) Recombinant cd2 binding proteins and their use
KR102669477B1 (ko) 신규 항-pvr 항체 또는 이의 항원 결합 단편, 및 이의 용도
CN116802213A (zh) 重组cd3结合蛋白及其用途
WO2025146490A1 (en) Recombinant cd117 binding proteins and their use
JP2025521387A (ja) 抗－ｃｄ７３抗体およびｉｌ－２を含む融合タンパク質およびその用途
HK40114315A (zh) 包含抗cd73抗体和il-2的融合蛋白及其用途
US20250235534A1 (en) An LTBR Agonist In Combination Therapy Against Cancer
WO2023222827A1 (en) Anti-complement factor h antibodies
WO2025256479A1 (zh) 一种融合蛋白及其用途